1989
Survival in Children with Perinatally Acquired Human Immunodeficiency Virus Type 1 Infection
Scott G, Hutto C, Makuch R, Mastrucci M, O'Connor T, Mitchell C, Trapido E, Parks W. Survival in Children with Perinatally Acquired Human Immunodeficiency Virus Type 1 Infection. New England Journal Of Medicine 1989, 321: 1791-1796. PMID: 2594038, DOI: 10.1056/nejm198912283212604.Peer-Reviewed Original ResearchConceptsMedian survivalMedian ageHuman immunodeficiency virus type 1 (HIV-1) infectionHuman immunodeficiency virus type 1Virus type 1 infectionImmunodeficiency virus type 1Common first manifestationLymphoid interstitial pneumoniaIntravenous drug useProportional hazards analysisTime of diagnosisPneumocystis carinii pneumoniaHIV-1 infectionMedian survival timeType 1 infectionRecurrent bacterial infectionsJackson Memorial HospitalLong-term survivalYears of ageVirus type 1Candida esophagitisProgressive diseaseAntiviral treatmentBlood transfusionInterstitial pneumonia
1985
Prognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy. Identification of two groups of patients with prospects for prolonged survival
Ihde D, Matthews M, Makuch R, McIntire K, Eddy J, Seeff L. Prognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy. Identification of two groups of patients with prospects for prolonged survival. The American Journal Of Medicine 1985, 78: 399-406. PMID: 2579551, DOI: 10.1016/0002-9343(85)90330-4.Peer-Reviewed Original ResearchConceptsAlpha-fetoprotein levelsFibrolamellar carcinomaHepatocellular carcinomaSystemic chemotherapyNormal serum alpha-fetoprotein levelsHepatitis B serum markersNormal alpha-fetoprotein levelsSerum alpha-fetoprotein levelsElevated alpha-fetoprotein levelsAmbulatory performance statusHomogeneous clinical featuresAbsence of cirrhosisHepatitis B markersTime of diagnosisGroup of patientsInitiation of treatmentLack of jaundiceAmbulatory statusExtrahepatic metastasesPerformance statusImproved survivalIndolent coursePrognostic factorsClinical featuresSerum markers
1982
Flow cytometric analysis of DNA content of bone marrow cells in patients with plasma cell myeloma: clinical implications.
Bunn P, Krasnow S, Makuch R, Schlam M, Schechter G. Flow cytometric analysis of DNA content of bone marrow cells in patients with plasma cell myeloma: clinical implications. Blood 1982, 59: 528-35. PMID: 6800416, DOI: 10.1182/blood.v59.3.528.bloodjournal593528.Peer-Reviewed Original ResearchConceptsTumor DNA contentMyeloma patientsPlasma cell myelomaAneuploid tumor cellsPlasma cellsWaldenstrom's macroglobulinemiaCell myelomaTumor cellsTime of diagnosisTime of relapseIndependent prognostic significanceCourse of illnessClinical drug resistancePotential clinical usefulnessBone marrow cellsDNA contentClinical relapseRenal failureSerum creatininePrognostic significanceDiploid tumorsAneuploid tumorsDevelopment of aneuploidyClinical significanceClinical usefulnessFlow Cytometric Analysis of DNA Content of Bone Marrow Cells in Patients With Plasma Cell Myeloma: Clinical Implications
Bunn P, Krasnow S, Makuch R, Schlam M, Schechter G. Flow Cytometric Analysis of DNA Content of Bone Marrow Cells in Patients With Plasma Cell Myeloma: Clinical Implications. Blood 1982, 59: 528-535. DOI: 10.1182/blood.v59.3.528.528.Peer-Reviewed Original ResearchTumor DNA contentMyeloma patientsPlasma cell myelomaAneuploid tumor cellsPlasma cellsWaldenstrom's macroglobulinemiaCell myelomaTumor cellsIndependent prognostic significanceTime of diagnosisTime of relapseCourse of illnessClinical drug resistancePotential clinical usefulnessBone marrow cellsFlow cytometric analysisDNA contentClinical relapseRenal failureSerum creatininePrognostic significanceDiploid tumorsAneuploid tumorsDevelopment of aneuploidyClinical significance